Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jason H. Christiansen"'
Autor:
Paul S. Mischel, Hoon Kim, Roel G.W. Verhaak, Jason H. Christiansen, Nam-Phuong Nguyen, Vineet Bafna, Christian Hassig
Publikováno v:
Journal of Clinical Oncology. 38:3123-3123
3123 Background: In the KEYNOTE-059 study, the anti-PD-1 checkpoint inhibitor pembrolizumab was shown to have a modest overall response of 11.6%. Common predictors of response including, high microsatellite instability (MSI-H), PD-L1 expression, tumo
Autor:
Patrizia Gasparini, Livio Trusolino, J.W. Lee, J.F. Hechtman, Lu Wang, J. Hodgson, Alfredo Falcone, J.S. Ross, F. de Braud, Vi Kien Chiu, Chiara Gigliotti, Siraj M. Ali, Daniele Rossini, Seungtae Kim, Giovanni Fucà, F. Di Nicolantonio, Petros Nikolinakos, Chiara Cremolini, Federica Morano, G.M. Frampton, R. Patel, Alexa B. Schrock, Luca Novara, Kyle Gowen, A. Drilon, Serenella M. Pupa, Filippo Pietrantonio, Massimo Milione, Michele Prisciandaro, A. Zaniboni, Alberto Bardelli, Andrea Bertotti, Jason H. Christiansen, Gabriella Sozzi, M. Di Bartolomeo, V.A. Miller
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(6)
Background Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to comprehensively characterize the clinical, pathological and molecular landscape of
Autor:
J.W. Lee, Massimo Milione, Michele Prisciandaro, Giovanni Fucà, Salvatore Corallo, Beatrice Borelli, Alexa B. Schrock, Alberto Bardelli, Vi Kien Chiu, A. Drilon, Filippo Pietrantonio, Daniele Rossini, F. de Braud, F. Di Nicolantonio, Livio Trusolino, C. Cremolini, A. Zaniboni, Jason H. Christiansen, A. Falcone, Federica Morano, C. Cagnazzo
Publikováno v:
Annals of Oncology. 28:vi6-vi7
Autor:
Daniel P. Cahill, Priscilla Kaliopi Brastianos, Heather Ely, Jason H. Christiansen, Ian M. Silverman, Gabriele Schackert, Tareq A. Juratli, Shilpa S. Tummala, Ganesh M. Shankar
Publikováno v:
Journal of Clinical Oncology. 36:e14028-e14028
e14028Background: Although a significant proportion of aggressive meningiomas acquire TERT promoter (TERTp) mutations which drive TERT overexpression during progression, alternative mechanisms of t...
Autor:
Alfredo Falcone, Salvatore Siena, Giovanni Fucà, Bosun Min, Jeeyun Lee, Jason H. Christiansen, Niall C. Tebbutt, Seung Tae Kim, Federica Di Nicolantonio, Siraj M. Ali, Jaclyn F. Hechtman, Carlotta Antoniotti, Alberto Bardelli, Filippo de Braud, Chiara Cremolini, Danielle Murphy, Sabine Tejpar, Filippo Pietrantonio, Alexa B. Schrock, Jeffrey S. Ross
Publikováno v:
Journal of Clinical Oncology. 35:589-589
589 Background: ALK, ROS1, and NTRKs fusions occur in 0.2-2.4% of CRCs, and represent therapeutic targets, as indicated by promising reports of individual patients treated with tyrosine kinase inhibitors. Clinical and molecular features of mCRCs harb
Autor:
Steven J. Potts, Maria Aslam, Cheng Ean Chee, Pratik S. Multani, Danielle Murphy, Darren Sigal, E. Gabriela Chiorean, Jennifer Lamoureux, Jonathan Polikoff, Emma Dean, Patrick Pauwels, Simon Pacey, Jason H. Christiansen
Publikováno v:
Journal of Clinical Oncology. 35:619-619
619 Background: The STARTRK-2 trial is a potentially registration-enabling Phase 2 global basket trial of the tyrosine kinase inhibitor entrectinib in patients with solid tumors harboring NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusions. Phase 1 studie